Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 8—August 2020
Research Letter

Estimation of Coronavirus Disease Case-Fatality Risk in Real Time

Yang GeComments to Author  and Shengzhi SunComments to Author 
Author affiliations: The University of Georgia, Athens, Georgia, USA (Y. Ge); Boston University School of Public Health, Boston, Massachusetts, USA (S. Sun)

Main Article

Figure

Progression of coronavirus disease outbreak and changes in the case-fatality risk by crude and adjusted rates. Crude case-fatality risk is the cumulative number of deaths on a given day divided by the cumulative number of cases on the same day. We set the infectious period as 10 days (2); case-fatality risk as 3% (3); basic reproductive ratio (R0) as 2.5 (4); recovery rate as 1/13 day (5), that is, 13 days from illness onset to recovery; and the population size as 1 million. A) Changes in the nu

Figure. Progression of coronavirus disease outbreak and changes in the case-fatality risk by crude and adjusted rates. Crude case-fatality risk is the cumulative number of deaths on a given day divided by the cumulative number of cases on the same day. We set the infectious period as 10 days (2); case-fatality risk as 3% (3); basic reproductive ratio (R0) as 2.5 (4); recovery rate as 1/13 day (5), that is, 13 days from illness onset to recovery; and the population size as 1 million. A) Changes in the number of subpopulations over time after the first infection. B) Changes in crude case-fatality risk after 13th day of exposure and aCFR calculated by using Wilson et al.’s method (1) and by using Mizumoto et al.’s method (6). aCFR, adjusted case-fatality risk.

Main Article

References
  1. Wilson  N, Kvalsvig  A, Barnard  LT, Baker  MG. Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality. Emerg Infect Dis. 2020;26: Epub ahead of print. DOIPubMedGoogle Scholar
  2. Guan  W-J, Ni  Z-Y, Hu  Y, Liang  W-H, Ou  C-Q, He  J-X, et al.; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;NEJMoa2002032; Epub ahead of print. DOIPubMedGoogle Scholar
  3. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China] [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145–51.PubMedGoogle Scholar
  4. Li  Q, Guan  X, Wu  P, Wang  X, Zhou  L, Tong  Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382:1199–207; Epub ahead of print. DOIPubMedGoogle Scholar
  5. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020 Feb 24 [cited 2020 Mar 27]. https://www.who.int/docs/default- source/coronaviruse/who-china-joint- mission-on-covid-19-final-report.pdf
  6. Mizumoto  K, Chowell  G. Estimating risk for death from 2019 novel coronavirus disease, China, January–February 2020. Emerg Infect Dis. 2020;26: Epub ahead of print. DOIPubMedGoogle Scholar

Main Article

Page created: April 21, 2020
Page updated: July 19, 2020
Page reviewed: July 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external